Država: Velika Britanija
Jezik: angleščina
Source: MHRA (Medicines & Healthcare Products Regulatory Agency)
Letrozole
Teva UK Ltd
L02BG04
Letrozole
2.5mg
Oral tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 08030401; GTIN: 5017007046219 5017007046318
PAGE 1 OF 7 PACKAGE LEAFLET PAGE 2 OF 7 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT LETROZOLE 2.5 MG FILM-COATED TABLETS READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE, BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What Letrozole is and what it is used for 2. What you need to know before you take Letrozole 3. How to take Letrozole 4. Possible side effects 5. How to store Letrozole 6. Contents of the pack and other information 1. WHAT LETROZOLE IS AND WHAT IT IS USED FOR WHAT LETROZOLE IS AND HOW IT WORKS Letrozole Tablets contain an active substance called letrozole. It belongs to a group of medicines called aromatase inhibitors. It is a hormonal (or “endocrine”) breast cancer treatment. Growth of breast cancer is frequently stimulated by oestrogens which are female sex hormones. Letrozole reduces the amount of oestrogen by blocking an enzyme (“aromatase”) involved in the production of oestrogens and therefore may block the growth of breast cancer that needs oestrogens to grow. As a consequence,tumour cells slow or stop growing and/or spreading to other parts of the body. WHAT LETROZOLE IS USED FOR Letrozole is used to treat breast cancer in women who have gone through menopause i.e cessation of periods. It is used to help prevent the cancer from happening again. It can be used as first treatment before breast cancer surgery in case immediate surgery is not suitable or it can be used as first treatment after breast cancer surgery or following five years treatment with tamoxifen. Letrozole is also used to prevent breast tumour spreadin Preberite celoten dokument
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Letrozole 2.5 mg film-coated tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 2.5mg letrozole. Excipient with known effect: each tablet contains 61.5mg lactose monohydrate. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Film-coated tablet. Yellow film-coated round biconvex tablets, debossed with L9OO on one side and 2.5 on the other side. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS • Adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer. • Extended adjuvant treatment of hormone-dependent-invasive breast cancer in postmenopausal women who have received prior standard adjuvant tamoxifen therapy for 5 years. • First-line treatment in postmenopausal women with hormone-dependent advanced breast cancer. • Advanced breast cancer after relapse or disease progression in women with natural or artificially induced postmenopausal endocrine status, who have previously been treated with anti-oestrogens. • Neo-adjuvant treatment of postmenopausal women with hormone receptor positive, HER-2 negative breast cancer where chemotherapy is not suitable and immediate surgery not indicated. Efficacy has not been demonstrated in patients with hormone-receptor negative breast cancer. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology _Adult and elderly patients _ The recommended dose of letrozole is 2.5mg once daily. No dose adjustment is required for elderly patients. In patients with advanced or metastatic breast cancer, treatment with letrozole should continue until tumour progression is evident. In the adjuvant and extended adjuvant setting, treatment with letrozole should continue for 5 years or until tumour relapse occurs, whichever is first. In the adjuvant setting a sequential treatment schedule (letrozole 2 years followed by tamoxifen 3 years) could also be considered (see sections 4.4 and 5.1). In the neoadjuvant setting, treatment with letrozole cou Preberite celoten dokument